Paltusotine, a Novel Oral Somatostatin Receptor Ligand in the Management of Acromegaly

Journal Article Paltusotine, a Novel Oral Somatostatin Receptor Ligand in the Management of Acromegaly Get access David S McLaren, David S McLaren Departments of Endocrinology, Leeds Centre for Diabetes & Endocrinology, Leeds Teaching Hospital NHS Trust, Leeds LS9 7TF, UKDivision of Cardiovascular and Diabetes Research, Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds LS2 9JT, UK Search for other works by this author on: Oxford Academic Google Scholar Robert D Murray Robert D Murray Departments of Endocrinology, Leeds Centre for Diabetes & Endocrinology, Leeds Teaching Hospital NHS Trust, Leeds LS9 7TF, UKDivision of Cardiovascular and Diabetes Research, Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds LS2 9JT, UK Correspondence: Robert D. Murray, MD, FRCP, Leeds Centre for Diabetes & Endocrinology, Leeds Teaching Hospitals NHS Trust, St James’s University Hospital, Beckett Street Leeds, LS9 7TF, UK. Email: robertmurray@nhs.net. https://orcid.org/0000-0001-6730-6109 Search for other works by this author on: Oxford Academic Google Scholar The Journal of Clinical Endocrinology & Metabolism, Volume 108, Issue 5, May 2023, Pages e193–e194, https://doi.org/10.1210/clinem/dgac762 Published: 30 December 2022 Article history Received: 07 December 2022 Editorial decision: 27 December 2022 Published: 30 December 2022 Corrected and typeset: 25 January 2023